• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815).
  

PubMed=10752474; DOI=10.1007/s002620050015; PMCID=PMC11037162
Slingluff C.L. Jr., Colella T.A., Thompson L., Graham D.D., Skipper J.C.A., Caldwell J., Brinckerhoff L., Kittlesen D.J., Deacon D.H., Oei C., Harthun N.L., Huczko E.L., Hunt D.F., Darrow T.L., Engelhard V.H.
Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
Cancer Immunol. Immunother. 48:661-672(2000)

PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209
Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J., Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.
Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma.
Cancer Res. 64:1157-1163(2004)

PubMed=15378283; DOI=10.1007/s00262-004-0592-y; PMCID=PMC11032761
Hogan K.T., Sutton J.N., Chu K.U., Caldwell-Busby J.A., Shabanowitz J., Hunt D.F., Slingluff C.L. Jr.
Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members.
Cancer Immunol. Immunother. 54:359-371(2005)

PubMed=20856146; DOI=10.1097/CMR.0b013e32833fafb4; PMCID=PMC3229868
Mikesh L.M., Kumar M., Erdag G., Hogan K.T., Molhoek K.R., Mayo M.W., Slingluff C.L. Jr.
Evaluation of molecular markers of mesenchymal phenotype in melanoma.
Melanoma Res. 20:485-495(2010)

PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6; PMCID=PMC3131461
Molhoek K.R., Shada A.L., Smolkin M., Chowbina S., Papin J., Brautigan D.L., Slingluff C.L. Jr.
Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.
Melanoma Res. 21:274-284(2011)

PubMed=26405815; DOI=10.1371/journal.pone.0138210; PMCID=PMC4583389
Capaldo B.J., Roller D.G., Axelrod M.J., Koeppel A.F., Petricoin E.F. 3rd, Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.
Systems analysis of adaptive responses to MAP kinase pathway blockade in BRAF mutant melanoma.
PLoS ONE 10:E0138210-E0138210(2015)

PubMed=26673621; DOI=10.18632/oncotarget.6548; PMCID=PMC4823068
Roller D.G., Capaldo B.J., Bekiranov S., Mackey A.J., Conaway M.R., Petricoin E.F. 3rd, Gioeli D., Weber M.J.
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.
Oncotarget 7:2734-2753(2016)